氯氮平对精神分裂症患者迟发性运动障碍的疗效。
Clozapine efficacy in tardive dyskinesia in schizophrenic patients.
作者信息
Bassitt D P, Louzã Neto M R
机构信息
Institute of Psychiatry, Medical School, University of São Paulo, SP, Brasil.
出版信息
Eur Arch Psychiatry Clin Neurosci. 1998;248(4):209-11. doi: 10.1007/s004060050039.
Tardive dyskinesia (TD) is a long-term severe complication of antipsychotic treatment, with mean prevalence of 20-35%. The aim of this study was to evaluate effects of clozapine in severe TD. In an open trial seven patients with schizophrenia and severe TD were given clozapine for 6 months. Tardive dyskinesia severity was evaluated with AIMS and ESRS and schizophrenic psychopathology with PANSS. Clozapine mean dose at the end of the study was 392.86 mg/day. A mean reduction of 52% was observed in ESRS scores for TD. Two patients also had dystonic movements, and there was 50% reduction in one of them and complete remission in the other. There was also a 27% mean reduction in PANSS scores. Clozapine seems to be an alternative in the treatment of schizophrenic patients with severe TD.
迟发性运动障碍（TD）是抗精神病药物治疗的一种长期严重并发症，平均患病率为20%-35%。本研究的目的是评估氯氮平对重度TD的疗效。在一项开放性试验中，7例患有精神分裂症和重度TD的患者接受了6个月的氯氮平治疗。采用异常不自主运动量表（AIMS）和异常运动评定量表（ESRS）评估迟发性运动障碍的严重程度，采用阳性和阴性症状量表（PANSS）评估精神分裂症的精神病理学症状。研究结束时氯氮平的平均剂量为392.86毫克/天。观察到TD的ESRS评分平均降低了52%。两名患者还出现了张力障碍性运动，其中一名患者的症状减轻了50%，另一名患者完全缓解。PANSS评分也平均降低了27%。氯氮平似乎是治疗重度TD的精神分裂症患者的一种替代药物。
Zotero 插件